Agios Pharmaceuticals Inc 2020 SR
The report marks the inaugural ESG disclosure for Agios Pharmaceuticals, covering the 2019 fiscal year. It highlights the company's commitment to cellular metabolism research and its success in bringing two precision oncology medications to market. The report details patient access initiatives, including a case study on drug delivery during the COVID-19 pandemic, and reports on workforce diversity with women representing 55% of the total headcount. Additionally, the company aligned its disclosures with SASB standards for the Biotechnology and Pharmaceuticals industry and the UN Sustainable Development Goals.
Company: Agios Pharmaceuticals Inc
Sector: Health Care
Country: United States
Year: 2020
Type: SR
Pages: 31
Agios Pharmaceuticals Inc
ESG Report
The report marks the inaugural ESG disclosure for Agios Pharmaceuticals, covering the 2019 fiscal year. It highlights the company's commitment to cellular metabolism research and its success in bringing two precision oncology medications to market. The report details patient access initiatives, including a case study on drug delivery during the COVID-19 pandemic, and reports on workforce diversity with women representing 55% of the total headcount. Additionally, the company aligned its disclosures with SASB standards for the Biotechnology and Pharmaceuticals industry and the UN Sustainable Development Goals.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2020
Reporting Period
Jan 1, 2019 - Dec 31, 2019
Fiscal Year
2019
Type
Sustainability Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Sustainable Development Goals
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Women on Board
Women in Management
Employees